Twice-daily to once-daily lopinavir/ritonavir pharmacokinetics-pharmacodynamics in pediatric patients

被引：0
|
作者：
Foissac, F. [1 ,2 ]
Blanche, S. [1 ]
Hirt, D. [1 ,2 ]
Treluyer, J. M. [1 ,2 ,3 ]
Urien, S. [1 ,2 ]
机构：
[1] Univ Paris 05, Unite Rech Clin, Paris Ctr, EA 3620, Paris, France
[2] INSERM Necker Cochin, CIC 0901, Paris, France
[3] Hop St Vincent de Paul, AP HP, Pharmacol Lab, Paris, France
来源：
FUNDAMENTAL & CLINICAL PHARMACOLOGY | 2010年 / 24卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：60 / 60
页数：1
相关论文
共 50 条
  • [31] Six-month comparison of bimatoprost once-daily and twice-daily with timolol twice-daily in patients with elevated intraocular pressure
    Sherwood, M
    Brandt, J
    SURVEY OF OPHTHALMOLOGY, 2001, 45 : S361 - S368
  • [32] Pharmacokinetics and tolerability of once- versus twice-daily lopinavir/ritonavir treatment in HIV-1-infected children
    la Porte, Charles
    van Heeswijk, Rolf
    Mitchell, Charles D.
    Zhang, Guijun
    Parker, Jackie
    Rongkavilit, Chokechai
    ANTIVIRAL THERAPY, 2009, 14 (04) : 603 - 606
  • [33] CONVERSION OF TWICE-DAILY TACROLIMUS TO ONCE-DAILY TACROLIMUS FORMULATION IN STABLE PEDIATRIC KIDNEY TRANSPLANT RECIPIENTS: PHARMACOKINETICS AND EFFICACY
    Min, Sang-Il
    Kang, Hee-Kyoung
    Ha, Jongwon
    Ha, Il-Soo
    Kim, Sang Joon
    TRANSPLANT INTERNATIONAL, 2013, 26 : 125 - 125
  • [34] CONVERSION OF TWICE-DAILY TACROLIMUS TO ONCE-DAILY TACROLIMUS FORMULATION IN STABLE PEDIATRIC KIDNEY TRANSPLANT RECIPIENTS: PHARMACOKINETICS AND EFFICACY
    Min, Sang-Il
    Kang, Hee-Kyoung
    Ha, Jongwon
    Ha, Il-Soo
    Min, Seung-Kee
    Kim, Sang Joon
    PEDIATRIC TRANSPLANTATION, 2013, 17 : 44 - 44
  • [35] Conversion of Twice-Daily Tacrolimus to Once-Daily Tacrolimus Formulation in Stable Pediatric Kidney Transplant Recipients: Pharmacokinetics and Efficacy
    Min, S. I.
    Ha, J.
    Kang, H. G.
    Ahn, S.
    Park, T.
    Park, D. D.
    Kim, S. M.
    Hong, H. J.
    Min, S. K.
    Ha, I. S.
    Kim, S. J.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2013, 13 (08) : 2191 - 2197
  • [36] Pharmacokinetics of nevirapine: Once-daily versus twice-daily dosing in the 2NN study
    Kappelhoff, BS
    Huitema, ADR
    van Leth, F
    Robinson, PA
    MacGregor, TR
    Lange, JMA
    Beijnen, JH
    HIV CLINICAL TRIALS, 2005, 6 (05): : 254 - 261
  • [37] COMPARISON OF ONCE-DAILY AND TWICE-DAILY NAFTIFINE CREAM REGIMENS WITH TWICE-DAILY CLOTRIMAZOLE IN THE TREATMENT OF TINEA PEDIS
    SMITH, EB
    WISS, K
    HANIFIN, JM
    JORDON, RE
    RAPINI, RP
    LASSER, AE
    KIRSCHENBAUM, MB
    MILLIKAN, LE
    PARISH, LC
    RAPAPORT, MJ
    ROENIGK, H
    ZAIAS, N
    DROMGOOLE, SH
    SEFTON, J
    DEGRYSE, R
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1990, 22 (06) : 1116 - 1117
  • [38] Once vs. twice-daily lopinavir/ritonavir in HIV-1-infected children
    Lyall, H.
    Inshaw, J.
    Saidi, Y.
    Cressey, T. R.
    Forcat, S.
    Riault, Y.
    Bastiaans, D.
    Burger, D.
    Koenigs, C.
    Kanjanavanit, S.
    Nayagam, D.
    Bunupuradah, T.
    Oliveira, R. Hugo
    della Negra, M.
    Giaquinto, C.
    Babiker, A. G.
    Compagnucci, A.
    Gibb, D. M.
    Goodall, R. L.
    AIDS, 2015, 29 (18) : 2447 - 2457
  • [39] Pharmacodynamics and Pharmacokinetics Following Once-Daily and Twice-Daily Dosing of Tiotropium Respimat® in Asthma Using Standardized Sample-Contamination Avoidance
    Beeh, Kai-Michael
    Kirsten, Anne-Marie
    Dusser, Daniel
    Sharma, Ashish
    Cornelissen, Piet
    Sigmund, Ralf
    Moroni-Zentgraf, Petra
    Dahl, Ronald
    JOURNAL OF AEROSOL MEDICINE AND PULMONARY DRUG DELIVERY, 2016, 29 (05) : 406 - 415
  • [40] A lopinavir/ritonavir-based once-daily regimen results in better compliance and is non-inferior to a twice-daily regimen through 96 weeks
    Molina, Jean-Michel
    Podsadecki, Thomas J.
    Johnson, Margaret A.
    Wilkin, Aimee
    Domingo, Pere
    Myers, Robert
    Hairrell, Jan M.
    Rode, Richard A.
    King, Martin S.
    Hanna, George J.
    AIDS RESEARCH AND HUMAN RETROVIRUSES, 2007, 23 (12) : 1505 - 1514
12345